Literature DB >> 10554637

Radiochemotherapy with paclitaxel: synchronization effects and the role of p53.

F Wenz1, S Greiner, F Germa, K Mayer, D Latz, K J Weber.   

Abstract

PURPOSE: We have studied the interaction of paclitaxel (Taxol) and radiation in V79 cells and human lymphoblasts with special emphasis on cell cycle effects and the role of p53.
MATERIAL AND METHODS: V79 cells in log- and plateau-phase and human lymphoblasts (p53wt TK6 and p53mut WTK1) were used. Paclitaxel was given for 2 hours. Survival was determined using clonogenic assays. Cell cycle analysis was done using DNA flow cytometry.
RESULTS: In V79 cells there was a dose dependent delay of colony formation after paclitaxel. The LD50 was about 0.4 microM with a 2-hour exposure. In exponentially growing cells, there was an accumulation of 40% of cells in G2/M 6 hours after paclitaxel. The dose modification factor was about 3.9 when radiation was given 6 hours after 0.3 microM paclitaxel for 2 hours. Synchronization experiments using serum starvation and induction showed that synchronization was not sufficient to induce a comparable dose modification factor. Human lymphoblasts with mutated p53 (WTK1, LD50 = 75 microM) were more resistant to paclitaxel than wild type p53 cells (TK6, LD50 = 25 microM).
CONCLUSION: The radiosensitization induced by paclitaxel was critically dependent on the timing of irradiation and chemotherapy, although synchronization alone was not sufficient to explain the dose modification. Lymphoblasts with mutated p53 were less sensitive than wild type p53 cells.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10554637     DOI: 10.1007/bf03215919

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN: 0179-7158            Impact factor:   3.621


  23 in total

1.  Abrogation of p53 function by HPV16 E6 gene delays apoptosis and enhances mutagenesis but does not alter radiosensitivity in TK6 human lymphoblast cells.

Authors:  Y Yu; C Y Li; J B Little
Journal:  Oncogene       Date:  1997-04-10       Impact factor: 9.867

2.  Cytotoxicity and cell-cycle effects of paclitaxel when used as a single agent and in combination with ionizing radiation.

Authors:  N Gupta; L J Hu; D F Deen
Journal:  Int J Radiat Oncol Biol Phys       Date:  1997-03-01       Impact factor: 7.038

3.  The response of proliferating cell nuclear antigen to ionizing radiation in human lymphoblastoid cell lines is dependent on p53.

Authors:  F Wenz; E I Azzam; J B Little
Journal:  Radiat Res       Date:  1998-01       Impact factor: 2.841

4.  A p53-dependent mouse spindle checkpoint.

Authors:  S M Cross; C A Sanchez; C A Morgan; M K Schimke; S Ramel; R L Idzerda; W H Raskind; B J Reid
Journal:  Science       Date:  1995-03-03       Impact factor: 47.728

5.  X-ray induced changes in immunostaining of proliferating cell nuclear antigen (PCNA) in V79 hamster fibroblasts.

Authors:  F Lohr; H Hof; K J Weber; D Latz; F Wenz
Journal:  Strahlenther Onkol       Date:  1998-11       Impact factor: 3.621

6.  Kinetics of mitotic arrest and apoptosis in murine mammary and ovarian tumors treated with taxol.

Authors:  L Milas; N R Hunter; B Kurdoglu; K A Mason; R E Meyn; L C Stephens; L J Peters
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

7.  Enhancement of tumor radioresponse of a murine mammary carcinoma by paclitaxel.

Authors:  L Milas; N R Hunter; K A Mason; B Kurdoglu; L J Peters
Journal:  Cancer Res       Date:  1994-07-01       Impact factor: 12.701

8.  Changes in radiation survival curve parameters in human tumor and rodent cells exposed to paclitaxel (Taxol).

Authors:  J Liebmann; J A Cook; J Fisher; D Teague; J B Mitchell
Journal:  Int J Radiat Oncol Biol Phys       Date:  1994-06-15       Impact factor: 7.038

9.  Effect of paclitaxel (taxol) alone and in combination with radiation on the gastrointestinal mucosa.

Authors:  K A Mason; L Milas; L J Peters
Journal:  Int J Radiat Oncol Biol Phys       Date:  1995-07-30       Impact factor: 7.038

10.  Absence of radiation-induced G1 arrest in two closely related human lymphoblast cell lines that differ in p53 status.

Authors:  J B Little; H Nagasawa; P C Keng; Y Yu; C Y Li
Journal:  J Biol Chem       Date:  1995-05-12       Impact factor: 5.157

View more
  5 in total

1.  Preliminary results of simultaneous radiochemotherapy with paclitaxel for urinary bladder cancer.

Authors:  J Dunst; C Weigel; H Heynemann; A Becker
Journal:  Strahlenther Onkol       Date:  1999-10       Impact factor: 3.621

2.  Phase II trial of a simultaneous radiochemotherapy with cisplatinum and paclitaxel in combination with hyperfractionated-accelerated radiotherapy in locally advanced head and neck tumors.

Authors:  Thomas Kuhnt; Axel Becker; Marc Bloching; Johannes Schubert; Gunther Klautke; Rainer Fietkau; Juergen Dunst
Journal:  Med Oncol       Date:  2006       Impact factor: 3.738

3.  Radiosensitizing effect of carboplatin and paclitaxel to carbon-ion beam irradiation in the non-small-cell lung cancer cell line H460.

Authors:  Nobuteru Kubo; Shin-ei Noda; Akihisa Takahashi; Yukari Yoshida; Takahiro Oike; Kazutoshi Murata; Atsushi Musha; Yoshiyuki Suzuki; Tatsuya Ohno; Takeo Takahashi; Takashi Nakano
Journal:  J Radiat Res       Date:  2015-01-18       Impact factor: 2.724

4.  Timed, sequential administration of paclitaxel improves its cytotoxic effectiveness in a cell culture model.

Authors:  Viktória Fisi; Emese Kátai; Péter Bogner; Attila Miseta; Tamás Nagy
Journal:  Cell Cycle       Date:  2016-04-22       Impact factor: 4.534

5.  Comparison of the effects of photon versus carbon ion irradiation when combined with chemotherapy in vitro.

Authors:  Fabian Schlaich; Stephan Brons; Thomas Haberer; Jürgen Debus; Stephanie E Combs; Klaus-Josef Weber
Journal:  Radiat Oncol       Date:  2013-11-06       Impact factor: 3.481

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.